ASH 2022 | Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, briefly comments on the results of a Phase I study evaluating ABBV-383, a BCMA × CD3 bispecific antibody in patients with relapsed/refractory (R/R) multiple myeloma (NCT03933735). Prof. Vij explains that this agent eliminates the need for step-up dosing, therefore reducing the length of hospitalization. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.
